{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:57:02Z","timestamp":1693213022664},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00059-018-4686-2","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T11:27:08Z","timestamp":1521718028000},"page":"230-237","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipidsenkende Therapie im Alter"],"prefix":"10.1007","volume":"43","author":[{"given":"E.","family":"Windler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.-U.","family":"Beil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Klose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"4686_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K et al (2016) Association between lowering LDL-C and cardiovascular risk reductionamong different therapeutic interventions: a systematic review and meta-analysis. JAMA 316:1289\u20131297","journal-title":"JAMA"},{"key":"4686_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a\u00a0meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670\u20131681","journal-title":"Lancet"},{"key":"4686_CR3","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","volume":"256","author":"J Stamler","year":"1986","unstructured":"Stamler J, Wentworth D, Neaton JD (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256:2823\u20132828","journal-title":"JAMA"},{"key":"4686_CR4","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Lewington S, Whitlock G, Clarke R et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a\u00a0meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829\u20131839","journal-title":"Lancet"},{"key":"4686_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s13311-011-0054-0","volume":"8","author":"J Aoki","year":"2011","unstructured":"Aoki J, Uchino K (2011) Treatment of risk factors to prevent stroke. Neurotherapeutics 8:463\u2013474","journal-title":"Neurotherapeutics"},{"key":"4686_CR6","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"SM Boekholdt","year":"2012","unstructured":"Boekholdt SM, Arsenault BJ, Mora S et al (2012) Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a\u00a0meta-analysis. JAMA 307:1302\u20131309","journal-title":"JAMA"},{"key":"4686_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/hc0302.102575","volume":"105","author":"G Assmann","year":"2002","unstructured":"Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular M\u00fcnster (PROCAM) study. Circulation 105:310\u2013315","journal-title":"Circulation"},{"key":"4686_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/07853898909149929","volume":"21","author":"A Menotti","year":"1989","unstructured":"Menotti A, Keys A, Aravanis C et al (1989) Seven Countries Study. First 20-year mortality data in 12 cohorts of sixcountries. Ann Med 21:175\u2013179","journal-title":"Ann Med"},{"key":"4686_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/978-3-642-82987-1_2","volume-title":"Coronary Risk Factors in Japan and China","author":"R Bernhardt","year":"1987","unstructured":"Bernhardt R, Feng Z, Deng Y, Wang Z, Zeng J, Cheng S, Cremer P, Thiery J, Seidel D, Schettler G (1987) Coronary risk factors in China: a\u00a0comparative study of middle-aged workers in China and Germany. In: Stehle G, Bernhardt R (Hrsg) Coronary Risk Factors in Japan and China. Springer, Berlin, Heidelberg, S 22\u201353"},{"key":"4686_CR10","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S0140-6736(17)30752-3","volume":"389","author":"H Kaplan","year":"2017","unstructured":"Kaplan H, Thompson RC, Trumble BC et al (2017) Coronary atherosclerosis in indigenous South American Tsimane: a\u00a0cross-sectional cohort study. Lancet 389:1730\u20131739","journal-title":"Lancet"},{"key":"4686_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1365-2362.2007.01888.x","volume":"37","author":"G Assmann","year":"2007","unstructured":"Assmann G, Schulte H, Cullen P, Seedorf U (2007) Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular M\u00fcnster (PROCAM) study. Eur J Clin Invest 37:925\u2013932","journal-title":"Eur J Clin Invest"},{"key":"4686_CR12","first-page":"154","volume":"41","author":"P Cremer","year":"1989","unstructured":"Cremer P, Muche R, Kruse-L\u00f6sler B et al (1989) Risk of myocardial infarct in 40 to 60-year-old males in relation to potential risk factors of atherosclerosis. Intermediate evaluation of the G\u00f6ttingen risk, incidence and prevalence study following a\u00a05-year observation period. Versicherungsmedizin 41:154\u2013162","journal-title":"Versicherungsmedizin"},{"key":"4686_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/sj.ejcn.1602233","volume":"59","author":"BC Zyriax","year":"2005","unstructured":"Zyriax BC, Boeing H, Windler E (2005) Nutrition is a\u00a0powerful independent risk factor for coronary heart disease in women\u2014The CORA study: a\u00a0population-based case-control study. Eur J Clin Nutr 59:1201\u20131207","journal-title":"Eur J Clin Nutr"},{"key":"4686_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","volume":"64","author":"SM Boekholdt","year":"2014","unstructured":"Boekholdt SM, Hovingh GK, Mora S et al (2014) Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a\u00a0meta-analysis of statin trials. J\u00a0Am Coll Cardiol 64:485\u2013494","journal-title":"J Am Coll Cardiol"},{"key":"4686_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N\u00a0Engl J Med 354:1264\u20131272","journal-title":"N Engl J Med"},{"key":"4686_CR16","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1056\/NEJMc0707445","volume":"358","author":"S Kathiresan","year":"2008","unstructured":"Kathiresan S, Myocardial Infarction Genetics Consortium (2008) A PCSK9 missense variant associated with a\u00a0reduced risk of early-onset myocardial infarction. N\u00a0Engl J Med 358:2299\u20132300","journal-title":"N Engl J Med"},{"key":"4686_CR17","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference BA, Majeed F, Penumetcha R et al (2015) Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a\u00a02 \u00d7 2 factorial Mendelian randomization study. J\u00a0Am Coll Cardiol 65:1552\u20131561","journal-title":"J Am Coll Cardiol"},{"key":"4686_CR18","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1161\/01.CIR.103.22.2705","volume":"103","author":"EM Tuzcu","year":"2001","unstructured":"Tuzcu EM, Kapadia SR, Tutar E et\u00a0al (2001) High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103:2705\u20132710","journal-title":"Circulation"},{"key":"4686_CR19","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP et\u00a0al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N\u00a0Engl J Med 372:2387\u20132397","journal-title":"N Engl J Med"},{"key":"4686_CR20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB et\u00a0al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a\u00a0randomised controlled trial. Lancet 360:1623\u20131630","journal-title":"Lancet"},{"key":"4686_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","volume":"97","author":"TR Pedersen","year":"1998","unstructured":"Pedersen TR, Olsson AG, Faergeman O et\u00a0al (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97:1453\u20131460","journal-title":"Circulation"},{"key":"4686_CR22","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","volume":"264","author":"JP Kane","year":"1990","unstructured":"Kane JP, Malloy MJ, Ports TA et\u00a0al (1990) Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007\u20133012","journal-title":"JAMA"},{"key":"4686_CR23","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1001\/jama.280.23.2001","volume":"280","author":"D Ornish","year":"1998","unstructured":"Ornish D, Scherwitz LW, Billings JH et\u00a0al (1998) Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280:2001\u20132007","journal-title":"JAMA"},{"key":"4686_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a\u00a0randomized controlled trial. JAMA 291:1071\u20131080","journal-title":"JAMA"},{"key":"4686_CR25","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","volume":"110","author":"JC Tardif","year":"2004","unstructured":"Tardif JC, Gr\u00e9goire J, L\u2019Allier PL et\u00a0al (2004) Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110:3372\u20133377","journal-title":"Circulation"},{"key":"4686_CR26","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295:1556\u20131565","journal-title":"JAMA"},{"key":"4686_CR27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMoa054699","volume":"354","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Tuzcu EM, Brewer HB et\u00a0al (2006) Effect of ACAT inhibition on the progression of coronary atherosclerosis. N\u00a0Engl J Med 354:1253\u20131263","journal-title":"N Engl J Med"},{"key":"4686_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.297.5.499","volume":"297","author":"SJ Nicholls","year":"2007","unstructured":"Nicholls SJ, Tuzcu EM, Sipahi I et al (2007) Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297:499\u2013508","journal-title":"JAMA"},{"key":"4686_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","volume":"2","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Wiviott SD, Blazing MA et al (2017) Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol 2:547\u2013555","journal-title":"JAMA Cardiol."},{"key":"4686_CR30","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG et al (2017) Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a\u00a0prespecified secondary analysis of the FOURIER trial. Lancet 390:1962\u20131971","journal-title":"Lancet"},{"key":"4686_CR31","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T et al (2016) Effect of evolocumab on progression of coronary disease in Statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316:2373\u20132384","journal-title":"JAMA"},{"key":"4686_CR32","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.117.028271","volume":"135","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Lonn E, Paynter NP et al (2017) Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation 135:1979\u20131981","journal-title":"Circulation"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-018-4686-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T01:13:18Z","timestamp":1553217198000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-018-4686-2"}},"subtitle":["Wer profitiert von welchem Zielwert?"],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["4686"],"URL":"https:\/\/doi.org\/10.1007\/s00059-018-4686-2","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"22 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Windler, F.-U.\u00a0Beil, G.\u00a0Klose und J.\u00a0Thiery geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}